PMID- 11840263
OWN - NLM
STAT- MEDLINE
DCOM- 20020312
LR  - 20220331
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 16
IP  - 1
DP  - 2002 Jan
TI  - Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, 
      qualitative and quantitative PCR for diagnosis and for follow-up in chronic 
      myeloid leukemia: a study on 350 cases.
PG  - 53-9
AB  - For the diagnosis of CML and for monitoring of treatment response the detection 
      of the t(9;22)(q34;q11) or the BCR-ABL rearrangement is necessary. Chromosome 
      banding analysis (CA) is still the gold standard but other techniques like 
      Southern blot, fluorescence in situ hybridization (FISH) and polymerase chain 
      reaction (PCR) are available. We analyzed 350 CML patients at different stages of 
      disease in parallel with CA, interphase-FISH (IP-FISH), hypermetaphase-FISH 
      (HM-FISH) and RT-PCR. In 20 cases with no Ph(+) metaphases in CA, HM-FISH 
      detected 0.2 to 10% BCR-ABL(+)metaphases. After IP-FISH 107 samples were judged 
      as negative. However, in 17 of these samples HM-FISH detected BCR-ABL(+) 
      metaphases (0.3-11%), and in eight cases CA detected Ph(+) metaphases (2.5-25%). 
      A comparison of IP-FISH performed on uncultivated cells vs cells cultivated for 
      48 h in 70 cases revealed a higher proportion of BCR-ABL+ cells in the cultivated 
      samples. If nested PCR was negative, all other methods were negative in all cases 
      too. In addition, 94 cases were evaluated using real-time PCR (LightCycler 
      technology). The BCR-ABL/cABL ratio measured showed a high correlation with all 
      other methods. Interestingly, a wide range in the BCR-ABL/ABL ratio was observed 
      especially in patients who showed 100% Ph-positive metaphases in CA. In 
      conclusion, CA, IP-FISH, HM-FISH and real-time PCR give reliable results but 
      differences due to measurement of different target structures have to be kept in 
      mind when using these data for definition of remission status.
FAU - Schoch, C
AU  - Schoch C
AD  - Department of Internal Medicine III, University Hospital Grosshadern, 
      Ludwig-Maximilians-University, Munich, Germany.
FAU - Schnittger, S
AU  - Schnittger S
FAU - Bursch, S
AU  - Bursch S
FAU - Gerstner, D
AU  - Gerstner D
FAU - Hochhaus, A
AU  - Hochhaus A
FAU - Berger, U
AU  - Berger U
FAU - Hehlmann, R
AU  - Hehlmann R
FAU - Hiddemann, W
AU  - Hiddemann W
FAU - Haferlach, T
AU  - Haferlach T
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA, Neoplasm)
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
SB  - IM
MH  - B-Lymphocytes/ultrastructure
MH  - Biomarkers, Tumor/*genetics
MH  - Bone Marrow Examination
MH  - *Chromosome Banding
MH  - Computer Systems
MH  - Disease Progression
MH  - Follow-Up Studies
MH  - Fusion Proteins, bcr-abl/*genetics
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence/methods
MH  - Interphase
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL 
      Positive/diagnosis/*genetics/pathology/therapy
MH  - Metaphase
MH  - Neoplasm, Residual
MH  - *Philadelphia Chromosome
MH  - *Polymerase Chain Reaction/methods
MH  - RNA, Messenger/genetics
MH  - RNA, Neoplasm/genetics
MH  - Remission Induction
MH  - Treatment Outcome
MH  - Tumor Cells, Cultured/ultrastructure
EDAT- 2002/02/13 10:00
MHDA- 2002/03/13 10:01
CRDT- 2002/02/13 10:00
PHST- 2001/03/22 00:00 [received]
PHST- 2001/07/22 00:00 [accepted]
PHST- 2002/02/13 10:00 [pubmed]
PHST- 2002/03/13 10:01 [medline]
PHST- 2002/02/13 10:00 [entrez]
AID - 10.1038/sj.leu.2402329 [doi]
PST - ppublish
SO  - Leukemia. 2002 Jan;16(1):53-9. doi: 10.1038/sj.leu.2402329.